Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Dec;74(11):1805–1811. doi: 10.1038/bjc.1996.634

Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.

P Comella 1, G Frasci 1, G De Cataldis 1, N Panza 1, R Cioffi 1, C Curcio 1, M Belli 1, A Bianco 1, G Ianniello 1, L Maiorino 1, M Della Vittoria 1, J Perchard 1, G Comella 1
PMCID: PMC2077209  PMID: 8956797

Abstract

A multicentre randomised phase III trial in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) was undertaken to compare the therapeutic activity and toxicity of a cisplatin/carboplatin-etoposide-vinorelbine combination with that of a cisplatin-etoposide regimen. Patients with advanced (stage IIIB-IV) NSCLC were randomised, after stratification for stage (IIIB-IV) and performance status (0-1 and 2), to receive either (A) CDDP 40 mg m-2 + VP16 100 mg m-2 on days 1-3 as standard treatment or (B) CBDCA 250 mg m-2 on day 1 + CDDP 30 mg m-2 on days 2 and 3 + VP16 100 mg m-2 on days 1-3 + NVB 30 mg m-2 on day 1. Therapy was recycled on day 29 in both arms. We hypothesised a 15% minimum increment in the response rate with the experimental regimen over the 25% expected activity rate of the standard regimen. A two-stage design was chosen, which permitted the early termination of the trial (after the accrual of 52 patients in each arm) if the difference in response rates between the two regimens was less than 3% at the end of the first stage. A total of 112 patients (arm A = 57, arm B = 55) were enrolled in the study (53 with stage IIIB and 59 with stage IV), of which 105 eligible patients were evaluable for response on an "intention to treat' basis. Seven patients were excluded because they did not fulfil the inclusion criteria. Fifteen responses were observed in arm A (28%, 95% CI = 17-42) and 13 (one complete) in arm B (25%, 95% CI = 13-37). On multivariate logistic analysis, treatment did not affect the response rate, while stage IV and performance status 2 were significantly associated with a lower probability of response. Median survivals were similar in the two arms (31 vs 27 weeks). The experimental regimen was associated with an extremely poor median survival in patients with poor performance status (21 weeks). On Cox analysis, treatment failed to show a significant impact on survival: stage IV (relative risk = 1.6. CI = 1.0-2.6, P = 0.036) was the only prognostic variable significantly associated with a worse survival outcome and, although poor performance status adversely affected survival, this effect did not reach the level of statistical significance (relative risk = 1.6, CI = 0.98-2.5; P = 0.063). There were no significant differences in non-haematological toxicities between the two arms, although three patients in the control arm had to discontinue the treatment because of the persistence of severe nephrotoxicity (two patients) or neurotoxicity (one patient). In contrast, a significant increase in both neutropenia and thrombocytopenia was observed in the experimental arm. Four treatment-related deaths were registered in arm B (two due to neutropenic sepsis, one to myocardial failure and one to acute renal failure) compared with one toxic death (acute renal failure) in arm A. In view of these results, the trial was stopped and the null hypothesis (< 15% increase in response rate with the experimental regimen) has been accepted. Therefore, our combination does not deserve further evaluation as first-line treatment in advanced NSCLC patients. As our data suggest that an aggressive chemotherapy might have a negative impact on survival of patients with poor performance status, trials to evaluate the activity of new regimens should be conducted separately for each subset of patients with different performance status.

Full text

PDF
1805

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ardizzoni A., Addamo G. F., Baldini E., Borghini U., Portalone L., De Marinis F., Lionetto R., Conte P. F., Bruzzi P., Pennucci M. C. Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force. Br J Cancer. 1995 Jan;71(1):115–119. doi: 10.1038/bjc.1995.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bonomi P. D., Finkelstein D. M., Ruckdeschel J. C., Blum R. H., Green M. D., Mason B., Hahn R., Tormey D. C., Harris J., Comis R. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989 Nov;7(11):1602–1613. doi: 10.1200/JCO.1989.7.11.1602. [DOI] [PubMed] [Google Scholar]
  3. Boring C. C., Squires T. S., Tong T. Cancer statistics, 1992. CA Cancer J Clin. 1992 Jan-Feb;42(1):19–38. doi: 10.3322/canjclin.42.1.19. [DOI] [PubMed] [Google Scholar]
  4. Casagrande J. T., Pike M. C. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics. 1978 Sep;34(3):483–486. [PubMed] [Google Scholar]
  5. Comella P., Casaretti R., Daponte A., Bartoli G. C., Parziale A. P., Palmieri G., Comella G. Combination of vinorelbine, cisplatin, and etoposide in advanced non-small cell lung carcinoma: a pilot study. J Chemother. 1994 Feb;6(1):67–71. doi: 10.1080/1120009x.1994.11741133. [DOI] [PubMed] [Google Scholar]
  6. Crino L., Tonato M., Darwish S., Meacci M. L., Corgna E., Di Costanzo F., Buzzi F., Fornari G., Santi E., Ballatori E. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol. 1990;26(1):52–56. doi: 10.1007/BF02940294. [DOI] [PubMed] [Google Scholar]
  7. Crinò L., Clerici M., Figoli F., Carlini P., Ceci G., Cortesi E., Carpi A., Santini A., Di Costanzo F., Boni C. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol. 1995 Apr;6(4):347–353. doi: 10.1093/oxfordjournals.annonc.a059183. [DOI] [PubMed] [Google Scholar]
  8. Cros S., Wright M., Morimoto M., Lataste H., Couzinier J. P., Krikorian A. Experimental antitumor activity of Navelbine. Semin Oncol. 1989 Apr;16(2 Suppl 4):15–20. [PubMed] [Google Scholar]
  9. Depierre A., Lemarie E., Dabouis G., Garnier G., Jacoulet P., Dalphin J. C. Efficacy of Navelbine (NVB) in non-small cell lung cancer (NSCLC). Semin Oncol. 1989 Apr;16(2 Suppl 4):26–29. [PubMed] [Google Scholar]
  10. Faulds D. Current options in the treatment of non-small cell lung cancer. Drugs. 1992;44 (Suppl 4):46–59. doi: 10.2165/00003495-199200444-00006. [DOI] [PubMed] [Google Scholar]
  11. Grilli R., Oxman A. D., Julian J. A. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol. 1993 Oct;11(10):1866–1872. doi: 10.1200/JCO.1993.11.10.1866. [DOI] [PubMed] [Google Scholar]
  12. Hainsworth J. D., Johnson D. H., Hande K. R., Greco F. A. Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens. Am J Clin Oncol. 1989 Aug;12(4):345–349. doi: 10.1097/00000421-198908000-00014. [DOI] [PubMed] [Google Scholar]
  13. Ihde D. C. Chemotherapy of lung cancer. N Engl J Med. 1992 Nov 12;327(20):1434–1441. doi: 10.1056/NEJM199211123272006. [DOI] [PubMed] [Google Scholar]
  14. Langer C. J., Leighton J. C., Comis R. L., O'Dwyer P. J., McAleer C. A., Bonjo C. A., Engstrom P. F., Litwin S., Ozols R. F. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995 Aug;13(8):1860–1870. doi: 10.1200/JCO.1995.13.8.1860. [DOI] [PubMed] [Google Scholar]
  15. Le Chevalier T., Brisgand D., Douillard J. Y., Pujol J. L., Alberola V., Monnier A., Riviere A., Lianes P., Chomy P., Cigolari S. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360–367. doi: 10.1200/JCO.1994.12.2.360. [DOI] [PubMed] [Google Scholar]
  16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  17. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  19. Sculier J. P., Klastersky J., Giner V., Bureau G., Thiriaux J., Dabouis G., Efremidis A., Ries F., Berchier M. C., Sergysels R. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol. 1994 Feb;12(2):353–359. doi: 10.1200/JCO.1994.12.2.353. [DOI] [PubMed] [Google Scholar]
  20. Stuart-Low W. Case of a Man with a singularly Symmetrical Syphilitic Septum. Proc R Soc Med. 1909;2(LARYNGOL):100–100. doi: 10.1177/003591570900200572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Thall P. F., Simon R., Ellenberg S. S., Shrager R. Optimal two-stage designs for clinical trials with binary response. Stat Med. 1988 May;7(5):571–579. doi: 10.1002/sim.4780070504. [DOI] [PubMed] [Google Scholar]
  22. Weick J. K., Crowley J., Natale R. B., Hom B. L., Rivkin S., Coltman C. A., Jr, Taylor S. A., Livingston R. B. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1991 Jul;9(7):1157–1162. doi: 10.1200/JCO.1991.9.7.1157. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES